These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 24486108)
21. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma. Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135 [TBL] [Abstract][Full Text] [Related]
22. Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT. Jeong HS; Baek CH; Son YI; Choi JY; Kim HJ; Ko YH; Chung JH; Baek HJ Clin Endocrinol (Oxf); 2006 Sep; 65(3):402-7. PubMed ID: 16918964 [TBL] [Abstract][Full Text] [Related]
23. The Comparison of Computed Tomography Perfusion, Contrast-Enhanced Computed Tomography and Positron-Emission Tomography/Computed Tomography for the Detection of Primary Esophageal Carcinoma. Genc B; Kantarci M; Sade R; Orsal E; Ogul H; Okur A; Aydin Y; Karaca L; Eroğlu A Med Princ Pract; 2016; 25(3):254-9. PubMed ID: 26784024 [TBL] [Abstract][Full Text] [Related]
24. A retrospective study comparing contrast-enhanced computed tomography with 18F-FDG-PET/CT in the early follow-up of patients with retroperitoneal sarcomas. Niccoli-Asabella A; Altini C; Notaristefano A; Merenda N; Altieri ML; Stabile-Ianora AA; Fanelli M; Rubini G Nucl Med Commun; 2013 Jan; 34(1):32-9. PubMed ID: 23111380 [TBL] [Abstract][Full Text] [Related]
25. Diagnostic accuracy of integrated (18)F-FDG PET/CT for restaging patients with malignant germ cell tumours. Sharma P; Jain TK; Parida GK; Karunanithi S; Patel C; Sharma A; Thulkar S; Julka PK; Bal C; Kumar R Br J Radiol; 2014 Aug; 87(1040):20140263. PubMed ID: 24896199 [TBL] [Abstract][Full Text] [Related]
26. Response assessment of colorectal liver metastases with contrast enhanced CT/18F-FDG PET. García Vicente AM; Domínguez Ferreras E; Sánchez Pérez V; Poblete García VM; Villa Guzmán JC; Jiménez Aragón F; Pineda Pineda MD; Molino Trinidad C; Soriano Castrejón Á Eur J Radiol; 2013 Jun; 82(6):e255-61. PubMed ID: 23414715 [TBL] [Abstract][Full Text] [Related]
27. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients. Lee DY; Lee CH; Seo MJ; Lee SH; Ryu JS; Lee JJ Ann Nucl Med; 2014 Oct; 28(8):789-95. PubMed ID: 24965850 [TBL] [Abstract][Full Text] [Related]
28. FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy. De Iaco P; Musto A; Orazi L; Zamagni C; Rosati M; Allegri V; Cacciari N; Al-Nahhas A; Rubello D; Venturoli S; Fanti S Eur J Radiol; 2011 Nov; 80(2):e98-103. PubMed ID: 20688446 [TBL] [Abstract][Full Text] [Related]
29. Comparison of hybrid FDG PET/MRI compared with PET/CT in colorectal cancer staging and restaging: a pilot study. Paspulati RM; Partovi S; Herrmann KA; Krishnamurthi S; Delaney CP; Nguyen NC Abdom Imaging; 2015 Aug; 40(6):1415-25. PubMed ID: 26112492 [TBL] [Abstract][Full Text] [Related]
30. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC). Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145 [TBL] [Abstract][Full Text] [Related]
31. The influence of different contrast medium concentrations and injection protocols on quantitative and clinical assessment of FDG-PET/CT in lung cancer. Verburg FA; Kuhl CK; Pietsch H; Palmowski M; Mottaghy FM; Behrendt FF Eur J Radiol; 2013 Oct; 82(10):e617-22. PubMed ID: 23880426 [TBL] [Abstract][Full Text] [Related]
32. Serum carcinoembryonic antigen measurement, abdominal contrast-enhanced computed tomography, and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of colorectal cancer recurrence: a correlative study. Ozkan E; Soydal C; Araz M; Aras G Nucl Med Commun; 2012 Sep; 33(9):990-4. PubMed ID: 22842225 [TBL] [Abstract][Full Text] [Related]
33. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736 [TBL] [Abstract][Full Text] [Related]
35. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels. Ozkan E; Soydal C; Araz M; Kir KM; Ibis E Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859 [TBL] [Abstract][Full Text] [Related]
36. Clinical value of ⁶⁸Ga-DOTATATE-PET/CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET). Albanus DR; Apitzsch J; Erdem Z; Erdem O; Verburg FA; Behrendt FF; Mottaghy FM; Heinzel A Eur J Radiol; 2015 Oct; 84(10):1866-72. PubMed ID: 26152870 [TBL] [Abstract][Full Text] [Related]
37. Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancer. Taus Á; Aguiló R; Curull V; Suárez-Piñera M; Rodríguez-Fuster A; Rodríguez de Dios N; Pijuan L; Zuccarino F; Vollmer I; Sánchez-Font A; Belda-Sanchis J; Arriola E Arch Bronconeumol; 2014 Mar; 50(3):99-104. PubMed ID: 24360985 [TBL] [Abstract][Full Text] [Related]
38. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited. Zhang X; Wu F; Han P Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754 [TBL] [Abstract][Full Text] [Related]
39. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy. Ohno Y; Koyama H; Yoshikawa T; Matsumoto K; Aoyama N; Onishi Y; Sugimura K AJR Am J Roentgenol; 2012 Jan; 198(1):75-82. PubMed ID: 22194481 [TBL] [Abstract][Full Text] [Related]
40. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice? Soyka JD; Veit-Haibach P; Strobel K; Breitenstein S; Tschopp A; Mende KA; Lago MP; Hany TF J Nucl Med; 2008 Mar; 49(3):354-61. PubMed ID: 18287263 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]